OncoCyte Corp (OCX)

Name: OncoCyte Corp (OCX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: OncoCyte Corp (OCX)

Stock Card

$2.83

$-0.33 (-10.44%)

As on 17-Jul-2025 09:30EDT

Market cap

$92 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

P/B Ratio

7.9

Div. Yield

0 %

OncoCyte Corp (OCX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.82 High: 2.98

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-4.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.3
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

28,599,300

10 Years Aggregate

CFO

$-188.48 Mln

EBITDA

$-182.40 Mln

Net Profit

$-277.60 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
OncoCyte Corp (OCX)	18.9	3.7	0.0	-14.0	-46.5	-36.9	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 17-Jul-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
OncoCyte Corp (OCX)	-4.8	-61.0	-85.2	-9.2	6.2	63.0	-70.1
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
OncoCyte Corp (OCX)	2.8	91.5	3.8	-58.2	-1,349.4	-584.1	--	7.9
Blueprint Medicines Corp (BPMC)	129.5	8,371.7	562.1	-155.7	-19.3	-47.5	--	24.4
Kronos BioÂ Inc (KRON)	0.9	53.7	9.2	-64.5	-550.5	-67.5	--	0.7

Shareholding Pattern

View Details

About OncoCyte Corp (OCX)

OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing... DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Read more

President, CEO & Director

Mr. Joshua Riggs
President, CEO & Director

Mr. Joshua Riggs
Headquarters

Irvine, CA
Website

https://www.oncocyte.com

FAQs for OncoCyte Corp (OCX)

What is the current share price of OncoCyte Corp (OCX) Today?

The share price of OncoCyte Corp (OCX) is $2.83 (NASDAQ) as of 17-Jul-2025 09:30 EDT. OncoCyte Corp (OCX) has given a return of -46.46% in the last 3 years.

What is the current PB & PE ratio of OncoCyte Corp (OCX)?

Since, TTM earnings of OncoCyte Corp (OCX) is negative, P/E ratio is not available.
The P/B ratio of OncoCyte Corp (OCX) is 7.92 times as on 17-Jul-2025, a 48 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.